The growing interest in patient-reported outcomes may require FDA to come up with new ways to incorporate such data in drug labeling as it also explores alternative methods for communicating this information to patients.
At an April 25 workshop on clinical outcome assessments in cancer trials, FDA officials said the agency is trying to...